HeartFlow has launched the next-generation interactive HeartFlow Plaque Analysis platform, which is designed to enhance clinical decision-making in assessing patient risk in suspected coronary artery disease (CAD).

The advanced tool integrates with FFRᴄᴛ to offer a comprehensive view of a patient's plaque burden, enabling personalised treatment plans.

The new HeartFlow Plaque Analysis platform provides clinicians with a non-invasive solution to quantify and characterise plaque in the coronary arteries.

By analysing CT angiogram (CCTA) scans, the platform creates a detailed 3D model of the arteries, offering insights into the volume and type of plaque present.

The integration of plaque quantification with lesion-specific FFRᴄᴛ values is a key feature of the interactive experience.

It presents a 3D plaque model and comprehensive analysis, covering various plaque types such as calcified, non-calcified, and low attenuation.  

The platform allows for displaying cross-sectional, colour-coded images of each plaque type along the vessel.

HeartFlow said the Plaque Analysis is recognised for its high level of accuracy, with a 95% agreement for total plaque volume measures when compared to the gold standard IVUS.

HeartFlow chief medical officer Campbell Rogers said: “Accurately diagnosing a patient’s risk for coronary artery disease is critical for determining the best treatment. Our new interactive plaque experience marks an exciting era in AI-enabled cardiac technology, where we are now the only company that offers a fully integrated view of a patient’s true burden of coronary artery disease.

“The elevated visualisation of Plaque Analysis integrated with our flagship FFRᴄᴛ Analysis, sets HeartFlow apart as a wholistic solution for CT analysis, enabling physicians to enhance personalised treatment decisions.”